Focus: Formycon is a German biotechnology company specializing in biosimilar development, with a focus on ophthalmology indications. The company operates as a mid-cap biotech player developing follow-on biologic versions of approved therapies.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Formycon to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead biosimilar product targeting VEGF-driven ocular diseases with clinical data supporting efficacy across three major ophthalmology indications.
Help build intelligence for Formycon
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Formycon's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Recently launched biosimilar targeting VEGF-A with broad indications in wet AMD and diabetes-related retinal disease, representing portfolio diversification.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo